Familial hypercholesterolaemia in children and adolescents: A new paediatric model of care

Journal of Paediatrics and Child Health

Volumn 49, Issue 4, 2013, Pages

  Martin, Andrew C ^a,b   Coakley, John ^e   Forbes, David A ^a,b   Sullivan, David R ^f,g   Watts, Gerald F ^c,d  

^a PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

adolescent; children; familial hypercholesterolaemia; LDL cholesterol; statin

Indexed keywords

BILE ACID SEQUESTRANT; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; ADOLESCENT; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHILD; CLINICAL FEATURE; CONSTIPATION; DIARRHEA; DIET; DISEASE PREDISPOSITION; DRUG SAFETY; ECHOGRAPHY; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC SCREENING; HEADACHE; HEPATITIS; HUMAN; LIFESTYLE MODIFICATION; MOLECULAR PATHOLOGY; MONOTHERAPY; MYOSITIS; PATIENT MONITORING; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SCHOOL CHILD; SCREENING TEST; SLEEP DISORDER;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; CHILD; CONGENITAL ABNORMALITIES; CORONARY STENOSIS; DISEASE PROGRESSION; EARLY DIAGNOSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; STANDARD OF CARE;

EID: 84876295898     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/jpc.12036     Document Type: Review

References (59)

1. Austin MA, Hutter CM, Zimmern RL, Humphries SE,. Genetic causes of monogenic heterozygous familial hypercholesterolaemia: a HuGE prevalence review. Am. J. Epidemiol. 2004; 160: 407-420.
2. Austin MA, Hutter CM, Zimmern RL, Humphries SE,. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am. J. Epidemiol. 2004; 160: 421-429.
3. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363: 369-370.
4. Neil HAW, Hammond T, Huxley R, Matthews DR, Humphries SE,. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. Br. Med. J. 2000; 321: 148.
5. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in the Netherlands. Atherosclerosis 2010; 209: 189-194.
6. Bates TR, Burnett JR, van Bockxmeer FM, Hamilton S, Arnolda L, Watts GF,. Detection of familial hypercholesterolaemia: a major treatment gap in preventative cardiology. Heart Lung Circ. 2008; 17: 411-413.
7. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. Br. Med. J. 2008; 337: a2423.
8. Daniels SR, Gidding SS, de Ferranti SD,. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 2011; 5: S30-37.
9. Descamps OS, Tenoutasse S, Stephenne X, et al. Management of familal hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a parent organization. Atherosclerosis 2011; 218: 272-280.
10. Watts GF, Sullivan DR, Poplawski N, et al. Familial hypercholesterolaemia: a model of care for Australasia. Atherosclerosis Suppl. 2011; 12: 221-263.
11. Soutar AK, Naoumova RP,. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 2007; 4: 214-225.
12. Marks D, Thorogood M, Neil HAW, Humphries SE,. A review on the diagnosis, natural history and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168: 1-14.
13. McGill HC Jr, McMahan CA,. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am. J. Cardiol. 1998; 82: 30T-36T.
14. Berenson GS, Srinivasan SR, Boa W, Newman WP 3rd, Tracy RE, Wattigney WA,. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med. 1998; 338: 1650-1656.
15. Raitakari OT, Juonala M, Kahonen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290: 2277-2283.
16. Dawson JD, Sonka M, Blecha MB, Lin W, Davis PH,. Risk factors associated with aortic and carotid intima-media thickness in adolescents and young adults: the Muscatine Offspring Study. J. Am. Coll. Cardiol. 2009; 53: 2273-2279.
17. de Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJP, Stroes ESG,. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002; 163: 193-197.
18. Rodenburg J, Vissers MN, Wiegman A, Trip MD, Bakker HD, Kastelein JJP,. Familial hypercholesterolaemia in children. Curr. Opin. Lipidol. 2004; 15: 405-411.
19. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116: 664-668.
20. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF,. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-581.
21. de Jongh S, Lilien MR, op't Roodt J, Stroes ESG, Bakker HD, Kastelein JJP,. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 2002; 40: 2117-2121.
22. Juonala M, Magnussen CG, Venn A, et al. Influence of age on associations between childhood risk factors and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study, the Childhood Determinants of Adult Health Study, the Bogalusa Heart Study, and the Muscatine Study for the International Childhood Cardiovascular Cohort (i3C) Consortium. Circulation 2010; 122: 2514-2520.
23. Jansen ACM, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 2004; 256: 482-490.
24. Daniels SR, Greer FR, the Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122: 198-208.
25. Starr B, Hadfield SG, Hutten BA, et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin. Chem. Lab. Med. 2008; 46: 791-803.
26. Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D,. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr. Opin. Lipidol. 2008; 19: 362-368.
27. Human Genetics Society of Australasia. Position Statement: Pre-Symptomatic and Predictive Testing in Children and Young People. 2008. Available from: http://www.hgsa.org.au/2009/12/%20pre-symptomatic-and- predictive-testing-in-children-and-young-people/ [accessed 23 January 2012].
28. Ritchie SK, Murphy EC-S, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: the cardiac project. Pediatrics 2010; 126: 260-265.
29. Wald DS, Bestwick JP, Wald NJ,. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. Br. Med. J. 2007; 335: 599.
30. Urbina EM, Williams RV, Alpert BS, et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009; 54: 919-950.
31. Ose L,. Diagnostic, clinical, and therapeutic aspects of familial hypercholesterolemia in children. Semin. Vasc. Med. 2004; 4: 51-57.
32. Viner R,. Barriers and good practice in transition from paediatric to adult care. J. R. Soc. Med. 2001; 94: 2-4.
33. Kavey R-EW, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart disease; and the interdisciplinary working group on quality of care and outcomes research. Circulation 2006; 114: 2710-2738.
34. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high risk lipid abnormalities in children and adolescents. Circulation 2007; 115: 1-20.
35. O'Gorman C, Higgins M, O'Neill M,. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects. Pediatr. Cardiol. 2009; 30: 482-489.
36. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst. Rev. 2010; 7: CD006401.
37. Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation 2009; 119: 1161-1175.
38. Obarzanek E, Kimm SY, Barton BA, et al. Long term safety and efficacy of a cholesterol lowering diet in children with elevated low density lipoprotein cholesterol: seven year results of the dietary intervention study in children (DISC). Pediatrics 2001; 107: 256-264.
39. Moruisi KG, Oosthuizen W, Opperman AM,. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J. Am. Coll. Nutr. 2006; 25: 41-48.
40. Amundsen AL, Ntanios F, van der Put N, Ose L,. Long-term compliance and changes in plasma lipids, plant sterols and carotenoids in children and parents with FH consuming plant sterol ester-enriched spread. Eur. J. Clin. Nutr. 2004; 58: 1612-1620.
41. McKenney JM, Ganz P, Wiggins BS, Saseen JS,. Statins. In:, Ballantyne CM, ed. Clinical Lipidology: A Companion to Braunwald's Heart Disease. Philadelphia: Saunders Elsevier, 2009; 253-280.
42. Toth PP,. Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. Drugs 2010; 70: 1363-1379.
43. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2007; 27: 1803-1810.
44. Arambepola C, Farmer AJ, Perera R, Neil HAW,. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis 2007; 195: 339-347.
45. Bottorff MB,. Statin safety and drug interactions: clinical implications. Am. J. Cardiol. 2006; 97: S27-31.
46. Avis HJ, Hutten BA, Gagne C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 2010; 55: 1121-1126.
47. McCrindle BW, Ose L, Marais AD,. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J. Pediatr. 2003; 143: 74-80.
48. National Institute for Health and Clinical Excellence. Ezetimibe for the Treatment of Primary (Heterozygous-Familial and Non-Familial) Hypercholesterolaemia; 2010. Available from: http://guidance.nice.%20org.uk/ nicemedia/live/11886/38213/38213.doc [accessed 23 January 2012].
49. Thorogood M, Seed M, De Mott K, Guideline Development Group. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. Br. J. Obstet. Gynaecol. 2009; 116: 478-479.
50. Avis HJ, Hutten BA, Twickler MT, et al. Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn? Curr. Opin. Lipidol. 2009; 20: 484-490.
51. Toleikyte I, Retterstøl K, Leren TP, et al. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation 2011; 124: 1606-1614.
52. Sweeney ME, Johnson RR,. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin. Drug Metab. Toxicol. 2007; 3: 441-450.
53. Drazen JM, D'Agostino RB, Ware JH, et al. Ezetimibe and cancer-an uncertain association. N. Engl. J. Med. 2008; 359: 1398-1399.
54. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192.
55. Thompson GR, Catapano A, Saheb S, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr. Opin. Lipidol. 2010; 21: 492-498.
56. HEART UK. FH Guideline Implementation Team Toolkit. 2010. Available from: http://www.heartuk.org.uk/FHToolkit [accessed 23 January 2012].
57. Wierzbicki AS, Humphries SE, Minhas R, Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. Br. Med. J. 2008; 337: a1095.
58. Tonkin A, Barter P, Best J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management-2005. Heart Lung Circ. 2005; 14: 275-291.
59. Datta BN, McDowell IF, Rees A,. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr. Opin. Lipidol. 2010; 21: 366-371.